Osteoporosis affects 1.2 million Australians and, in 2012, fractures due to osteoporosis and
osteopenia in Australians aged over 50 years cost $2.75 billion. Even minor minimal trauma …

Background Osteoporosis has a huge impact on public health, through the increased
morbidity, mortality and economic costs associated with resultant fractures. The goal is to …

Efficient therapies are available for the treatment of osteoporosis. Anti‐resorptive therapies,
including bisphosphonates and denosumab, increase bone mineral density (BMD) and …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

Treating osteoporosis: risks and management - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …

Osteoporosis is a systemic skeletal disorder leading to decreased bone mineralisation and a
propensity for fracture. The disease affects millions of people and is a source of significant …

Objective To review the comparative effectiveness of osteoporosis treatments, including the
bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in …

Fragility fractures are painful, debilitating, often life-changing and accounted for an
estimated 2.4% of pre-pandemic health care spending in the UK. Those who are older, frail …

Anabolic agents for the treatment of osteoporosis increase bone density, improve bone
strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their …

Antiresorptive therapies are used to increase bone strength in individuals with osteoporosis
and include five principal classes of agents: bisphosphonates, estrogens, selective estrogen …